clinical trial · NCT06815965
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
EIP Pharma Inc·phase2·completed·n = 26
Dementia With Lewy Bodies (DLB)neflamapimod
brief summary
The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
started
Oct 16, 2024
primary completion
Mar 11, 2026
completion
Mar 25, 2026
last updated
Apr 8, 2026
official title
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol